Antiviral drug

Mechanisms and common targets

Antiviral agents act at defined stages of the viral life cycle. Common mechanisms include:

• Entry and fusion inhibitors — block attachment to receptors or membrane fusion, preventing the virus from entering target cells.
• Nucleoside and nucleotide analogues — mimic natural nucleotides and cause premature termination or mutagenesis during genome replication.
• Polymerase inhibitors — bind viral polymerases or associated factors and reduce nucleic acid synthesis.
• Protease inhibitors — prevent processing of viral polyproteins required for assembly of infectious particles.
• Release inhibitors — hinder viral egress from infected cells, as with neuraminidase inhibitors used against influenza.
• Host-directed therapies and immunomodulators — modulate host pathways or immune responses to decrease viral replication or pathological inflammation.

Examples and therapeutic classes

Well known examples include acyclovir for herpesviruses, nucleoside reverse transcriptase inhibitors and protease inhibitors for HIV, neuraminidase inhibitors for influenza, and direct-acting antivirals that target hepatitis C virus protease or polymerase. Some agents are used acutely to shorten illness or prevent complications; others are given long term to suppress chronic infection. Combination regimens are common, particularly for HIV and hepatitis C, to increase efficacy and reduce resistance.

History and development

Early virology identified the challenge that antiviral therapy would need to avoid harming the host. Advances in cell culture, enzymology and molecular biology enabled the identification of viral enzymes and structural targets sufficiently distinct from host counterparts to permit selective inhibition. Demonstrated clinical successes transformed the field and made antiviral therapy a standard component of infectious disease care. Discussions of the early concept and debates about feasibility are captured in literature on viral chemotherapy.

Clinical uses, limitations and resistance

Antivirals are used for treatment and prophylaxis, to reduce symptoms, prevent severe disease, lower viral load and limit transmission. Limitations include the need for early administration in many acute infections, potential toxicity from off‑target effects, drug–drug interactions, and the emergence of resistant viral variants. Resistance arises through mutation of viral genes encoding drug targets; combination therapy and surveillance for resistance mutations are central mitigation strategies.

Drug development, regulation and future directions

Current research integrates small molecules, biologics such as monoclonal antibodies, host‑directed approaches and gene‑based techniques. Structural virology, high‑throughput screening and genomics have accelerated target discovery and rational drug design. Regulatory pathways include standard approval processes and, in emergencies, expedited or emergency use authorizations. Vaccines remain a primary prevention tool and usually complement treatment options. Ongoing goals include broader‑spectrum agents, improved oral formulations, reduced toxicity and rapid response capability for emerging viruses.

For foundational reading on virus biology and therapeutic strategies see materials on virus structure and replication, historical perspectives on host–pathogen interactions and parasitism, and reviews of concepts in viral chemotherapy.